- News & Publications
- CooperSurgical Completes $1.1B Acquisition of PARAGARD® IUD From Teva
CooperSurgical Completes $1.1B Acquisition of PARAGARD® IUD From Teva
On November 1, 2017, Carter Ledyard client CooperSurgical, Inc. completed its previously announced purchase of the assets and global rights and business of the PARAGARD® Intrauterine Device (IUD) product from Teva Pharmaceutical Industries Ltd. for a purchase price of approximately $1.1 billion in cash. CooperSurgical is a subsidiary of The Cooper Companies, Inc. (NYSE), a leading global medical device company operating in the vision care and women’s health industries. Carter Ledyard corporate partners David I. Karabell and Bryan J. Hall and corporate associate Anup Khatri handled this transaction for CooperSurgical, with assistance from corporate associates Brielle E. Kilmartin, Matthew B. James, Guy Ben-Ami and Matthew J. Schwartz. Corporate partner Austin D. Keyes and corporate counsel Ann B. Pace assisted with antitrust matters. Environmental partner Christine A. Fazio, tax counsel Jennifer H. MacDonald and real estate associate Rocco M. Sainato also assisted with the transaction.
We continue to monitor and report on recent COVID-19 developments. Please refer to our Response Group’s homepage, where you'll find advisories from numerous attorneys on a wide range of subjects.